Dekk-tec, Inc.

New Orleans, LA 70124

SBIR Award Summary

Total Number of Awards 29
Total Value of Awards $6.02MM
First Award Date 09/30/89
Most Recent Award Date 02/03/17

Key Personnel

Last Name Name Awards Contact
Morgan Lee Roy Morgan 29

29 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 02/03/17 - 01/31/18

The goal of this Phase I clinical trial will be to document safety and potential usefulness of 4- demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in combination with de-escalating doses of whole brain radiation therapy (WBRT), as binary therapy in subjects with advanced cancer involving the CNS [a Phase I clinical trial]. DM-CHOC-PEN...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/17 - 01/31/18

? DESCRIPTION (provided by applicant): The primary goal of this Phase I pediatric oncology clinical trial will be to evaluate the safety and use of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), as anticancer therapy for children with advanced cancer involving the central nervous system (CNS). DM-CHOC-PEN is a polychlorinated...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/16 - 01/31/17

? DESCRIPTION (provided by applicant): The primary goal of this Phase I pediatric oncology clinical trial will be to evaluate the safety and use of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), as anticancer therapy for children with advanced cancer involving the central nervous system (CNS). DM-CHOC-PEN is a polychlorinated ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-414
Budget: 02/01/16 - 01/31/17

? DESCRIPTION (provided by applicant): The primary goal of this Phase I pediatric oncology clinical trial will be to evaluate the safety and use of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), as anticancer therapy for children with advanced cancer involving the central nervous system (CNS). DM-CHOC-PEN is a polychlorinated...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbonate as anticancer therapy for patients with advanced cancer in a Phase II clinical trial. During pre-clinical studies DM-CHOC-PEN produced complet...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbonate as anticancer therapy for patients with advanced cancer in a Phase II clinical trial. During pre-clinical studies DM-CHOC-PEN produced complet...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/11 - 08/31/12

DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic tumor tissues, characteristic of fast growing cancers that characteristically have deficient vasculature and outgrow their blood supply. Both in v...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic tumor tissues, characteristic of fast growing cancers that characteristically have deficient vasculature and outgrow their blood supply. Both in v...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 08/06/09 - 07/31/10

DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative of 4-demethyl-penclomedine (DM-PEN) in patients with advanced cancer. The latter is the antitumor active, non-neurotoxic metabolite of penclomedin...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative of 4-demethyl-penclomedine (DM-PEN) in patients with advanced cancer. The latter is the antitumor active, non-neurotoxic metabolite of penclomedin...

Load More